Products with Chemosensitizers bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1556 | 5,5'-Dimethoxylariciresinol 4-O-glucoside |
| 1. 5,5'-Dimethoxylariciresinol-4'-O-beta-D-glucoside is shown to effectively enhance chemosensitivity of resistant cells, which makes it may be a suitable candidate for potential multidrug resistance (MDR)-reversing agents. | |
| BCN2563 | 4-Methylumbelliferone |
| 4-Methylumbelliferone is a hyaluronic acid (HA) synthesis inhibitor with an IC50 of 0.4 mM, which has antitumoral and antimetastatic effects. 4-Methylumbelliferone may inhibit the phosphorylation of HAS2 by PKC through the stimulation of O-GlcNAcylation; it also similarly ameliorates hypertriglyceridemia and hyperglycemia partly by modulating hepatic lipid metabolism and the antioxidant defense system along with increasing adiponectin levels. | |
| BCN2623 | Cimicifugoside |
| 1. Cimicifugoside is a novel specific nucleoside transport inhibitor that displays synergistic potentiation of methotrexate cytotoxicity. 2. Cimicifugoside is a phytoestrogen, it can selectively inhibit nicotinic acetylcholine receptor (nAChR) -mediated response in bovine chromaffin cells. 3. Cimicifugoside shows immunosuppressive activity, which is preferentially directed toward B-cell function with larger doses being required for suppression of T-cell function. | |
| BCN2964 | Cyclopamine |
| Cyclopamine is a Hedgehog (Hh) pathway antagonist with an IC50 of 46 nM in the Hh cell assay, it can increase levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. Cyclopamine as a novel, potent inhibitor of human breast cancer proliferation and estrogen responsiveness that could potentially be developed into a promising therapeutic agent for the treatment of breast cancer. Cyclopamine also can suppress the growth of leukemia and lymphoma cells. | |
